Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.58 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17187971 | 0.89 | OPRM1 (0.72) | KDM4ENPSR1OPRM1OPRD1OPRK1 | |
| SCHEMBL8236858 | 0.88 | KDM4E (0.61) | KDM4ENPSR1OPRM1OPRD1OPRK1 | |
| SCHEMBL4155932 | 0.85 | KDM4E (0.63) | KDM4ENPSR1OPRM1OPRD1OPRK1 | |
| SCHEMBL11282136 | 0.82 | OPRM1 (0.80) | KDM4ENPSR1OPRM1OPRD1OPRK1 | |
| SCHEMBL703650 | 0.81 | KDM4E (0.69) | KDM4ENPSR1OPRM1OPRD1OPRK1 | |
| SCHEMBL670971 | 0.79 | OPRM1 (0.56) | KDM4ENPSR1OPRM1OPRD1OPRK1 | |
| SCHEMBL14710358 | 0.79 | OPRM1 (0.53) | KDM4ENPSR1OPRM1OPRD1OPRK1 | |
| SCHEMBL702418 | 0.78 | KDM4E (0.66) | KDM4ENPSR1OPRM1OPRD1OPRK1 | |
| SCHEMBL10567213 | 0.77 | OPRM1 (0.53) | KDM4ENPSR1OPRM1OPRD1OPRK1 | |
| SCHEMBL4506478 | 0.77 | OPRM1 (0.53) | NPSR1OPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER INC | 2009-03-12 | — | — | US | disclosed |
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER INC | 2009-03-12 | — | — | US | disclosed |
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER INC | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | BACE2, BACE1, PMP22 | KDM4E 2960/4885NPSR1 696/4885OPRM1 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.